Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has...
International Phase 1 clinical trials expected to start in 2019 In France, the studies will be conducted at Institut Curie and Toulouse-Oncopole Clinical trials co-funded by Transgene and its collaboration partner NEC Transgene (TNG.PA) (Euronext Paris: TNG), a...
DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that the first 30 subjects have been...
A breakthrough approach for treatment of autoimmune and inflammatory diseases THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON PUBLICATION OF...
Innovation Pharmaceuticals (IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that BDD Pharma, the Company’s formulation partner in the area of Inflammatory Bowel Disease (IBD), has performed appropriate non-clinical...
Study Investigates Use of the Tack Endovascular System® for Focal Dissection Repair Following Drug-Coated Balloon Angioplasty in PAD Patients Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced...
Email
Text